December 15, 2022
Japan’s all-powerful reimbursement policy panel on December 14 approved the results of cost-effectiveness assessments (CEAs) for Insmed’s antibiotic Arikayce (amikacin), putting it in line for a downward price adjustment. Arikayce joined the NHI price list in May 2021 for the...read more